RecruitingAccepts healthy volunteers
Aimovig Pregnancy Exposure Registry
Amgen · NCT06150781
View Study & Apply (opens in a new tab)
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–99 · Women only
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 2842
- US sites recruiting
- 1
- Study start
- January 27, 2021
- Record last updated
- November 4, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The primary objective of this study is to estimate the proportion of major congenital malformations in infants of women with migraine exposed to erenumab-aooe during pregnancy compared to infants of women with migraine unexposed to erenumeb-aooe.
Being studied: erenumab-aooe
Conditions: Migraine
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Age 18 years or older (at time of signing the informed consent)
- Currently pregnant
- The outcome of the pregnancy must not be known
- Confirmed clinical diagnosis of migraine
Exclusion Criteria
- Women currently participating in another investigational device or investigational drug study, currently taking an investigational medicinal product, or having taken an investigational product within 3 months prior to last menstrual period (LMP) or during pregnancy. Other investigational procedures while participating in this study are excluded.
- Women exposed to any medications that target the calcitonin gene-related peptide (CGRP) pathway (ie, CGRP monoclonal antibody [mAb] or gepants) in the period from 5 half-lives prior to LMP through the end of pregnancy.
Recruiting US locations
IQVIA Virtual Site
Durham, NC 27703
Study contacts (from the official record)
- Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Similar studies in North Carolina
All neurology studies in North Carolina →- RecruitingHealthy volunteersPhase 1
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
Suninflam Inc
- Location
- Charlotte, NC + 9 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 1/Phase 2
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
Encoded Therapeutics
- Location
- Durham, NC + 9 other US sites
- Eligibility basics
- Ages 6 mo–17
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Charlotte, NC + 35 other US sites
- Eligibility basics
- Ages 18–65
- Recruiting
Diagnosing Epilepsy To EffeCT Change
Epiminder America, Inc.
- Location
- Charlotte, NC + 21 other US sites
- Eligibility basics
- Ages 18–75